Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech

Momenta will invest in three novel drugs and end development of all but two late-stage biosimilars under a new business strategy. The company is reducing its workforce by 50%, or about 110 employees.